Lab21 secures additional IP for Hepatitis C diagnostics
Lab 21 announced that it has completed an agreement to exclusively license the hepatitis C (HCV) diagnostic technology and associated patent applications of Dr. Carol Holland (TROY, MI, USA). The deal was brokered by UTEK-EKMS (CAMBRIDGE, MA, USA), a leading intellectual property (IP) management firm, on behalf of Dr. Holland.
"Lab 21 is committed to providing advanced healthcare testing services and licensing Dr. Holland's technology will allow us to further our development in the area of HCV testing." said Berwyn Clarke, Chief Scientific Officer of Lab 21. He continued: "HCV is a virus that is likely to resemble HIV in that antiviral drug resistance will become a significant issue as and when new small molecule drugs are licensed. The acquisition of this technology is a powerful tool in support of our commitment to develop resistance genotyping assays that will allow optimal clinical management of HCV patients."
The details and terms of the agreement were not disclosed.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Explaining how 2-D materials break at the atomic level
Cornell scientists build 'nano-keys' to bind cell receptors and trigger allergic reactions
How superbugs rapidly evolve
Imaging cells: New method enables clear, precise look inside - Researchers can now ‘see’ the fine structure and chemical composition of a human cell with unmatched clarity and precision
More than the sum of mutations - 165 new cancer genes identified with the help of machine learning
Sophisticated monitoring array to address mystery of uranium plume - Groundwater contamination remains significantly unchanged for 10 years
Making a better nitrate test kit
Making the Invisible Visible – Two-Step Mechanism Discovered that Enables Innate Immune System to Detect Viruses Like HIV Early - Understanding this mechanism could be helpful for the development of AIDS vaccines
Lab M completes move to new HQ
